APLMS will use Singapore, China and India to test how longevity science can translate into function, prevention and healthier lives at scale.
The Asia-Pacific Longevity Medicine Society (APLMS) is developing a regional model intended to move healthy longevity out of specialist settings and into everyday life, using Singapore, China and India as distinct environments in which to generate real-world evidence and test approaches to prevention. Its scope is substantial: the three countries together represent approximately 2.8 billion people – more than a third of the world’s population – but population size is only part of the proposition.
Hong Kong hosts the model’s public debut: APLMS will introduce and further develop SCI at the 2026 Asia-Pacific Healthy Longevity International Summit, running 1–4 October. The questions on the table are deceptively simple – what travels across cultures and healthcare systems, what needs reinventing locally, and whether any of this actually changes outcomes once it leaves the laboratory or the specialist clinic.
Longevity.Technology: Longevity medicine has become increasingly sophisticated at measuring aging; the more important test is whether those measurements translate into lives with more function, independence and resilience – and fewer years constrained by chronic disease. A biomarker can tell us something fascinating about aging biology; it cannot carry the shopping upstairs. The SCI model’s emphasis on real-world evidence across very different populations is therefore interesting, particularly because it treats technology as a means rather than the endpoint. Longevity medicine that stays confined to the premium clinic is, in the end, a hobby for the wealthy rather than a population-health strategy; its useful interventions have to find their way into ordinary healthcare, workplaces and communities, or they don’t much matter. That journey looks different in Singapore, China and India, and assuming otherwise – that what works in one population will travel neatly to another – is precisely the kind of assumption SCI is built to test rather than indulge. The arithmetic alone should focus the mind: at a scale of some 2.8 billion people, even a modest gain in functional health stops being modest. The interesting question is whether they can be demonstrated – then delivered.
Three countries, different laboratories
The thinking owes something to blue zones – those pockets of the world where people seem to age unusually well. What’s striking about many of them, on APLMS’s account, is the absence of anything exceptional: no particular wealth, no advanced healthcare, just ordinary people living ordinary lives amid strong daily habits, social bonds and cultural continuity that happen to compound rather well over decades. Whether that pattern generalizes is precisely the question SCI intends to test, rather than assume.
APLMS has selected Singapore, China and India precisely because they are not interchangeable. Singapore combines established public-health infrastructure and population-based healthcare with research in geroscience and precision medicine; its multicultural population and emphasis on prevention offer one environment in which longevity approaches can be evaluated in practice.
China – the world’s second-largest economy, home to more than 1.4 billion people – brings scale of a different order, alongside growing digital-health capabilities and extensive experience in population health. Its healthcare landscape also encompasses both modern medicine and longstanding culturally rooted health practices, providing another test of what translation means when scientific evidence meets existing behaviors and systems of care.
India, now the world’s most populous country, adds considerable heterogeneity in diet, culture, family structures and community life. APLMS also points to Ayurveda and its emphasis on daily routines, nutrition, sleep, physical activity and mental wellbeing; these traditions will sit alongside India’s developing scientific, healthcare and digital-health capabilities within the proposed model.
The intention is not to identify a single cultural recipe for longevity. Quite the reverse: SCI is conceived as an evidence-led translation network capable of separating principles that prove transferable from those that remain stubbornly local.
When the endpoint has legs
Central to the model is a shift in emphasis from surrogate measures toward function. Aging biology and biomarkers remain important, as do digital tools and emerging interventions; APLMS argues, however, that their value should ultimately be judged against mobility, independence, chronic disease burden, wellbeing and disability-free years.
That distinction matters. Longevity research increasingly has access to exquisitely granular measurements of biological processes, yet a statistically interesting movement in a biomarker does not automatically confer a clinically meaningful benefit. Function is messier. It is also difficult to ignore.
SCI will therefore look beyond what happens during a clinical encounter to the conditions accumulated over decades – diet and movement, certainly, but also social connection, environment, purpose, community participation and access to preventive care. Medicine and technology are positioned as tools for understanding, measuring and strengthening those foundations rather than substitutes for them.
Evidence in the wild
The real-world evidence component is where the model becomes more ambitious. Controlled studies remain essential for establishing efficacy and safety, but population health has an inconvenient habit of taking place under uncontrolled conditions – among different diets, healthcare infrastructures, socioeconomic circumstances and cultural expectations.
APLMS plans to establish an SCI Healthy Longevity Real-World Evidence and Translation Network, with initial work during 2026–27 expected to include a shared framework and pragmatic common outcomes, alongside opportunities for real-world studies, clinician education and implementation pathways.
A dedicated session at the Hong Kong summit – titled The SCI Healthy Longevity Model: Everyday Life, Real-World Evidence and Prevention at Scale – will begin that process, bringing together researchers, clinicians, healthcare leaders and implementation partners. The challenge will be to preserve enough methodological consistency to make findings useful while allowing sufficient local flexibility to make them relevant – scale without context is not quite scale.
Prevention leaves the waiting room
Perhaps the larger proposition is where SCI ultimately intends its findings to go. APLMS explicitly envisages pathways beyond premium longevity clinics and wellness services, extending evidence-based approaches into communities, workplaces, employers, insurers and established health systems.
That is a considerably tougher translational problem than offering another test or intervention to an already engaged longevity consumer. Prevention at population level must contend with accessibility, adherence, cultural acceptability and healthcare economics; what is biologically plausible must also become practically usable.
A wider proving ground
APLMS President Dr Tim Shi frames the ambition in much the same terms. The model, he said, is not intended to create another theoretical framework or search for a single formula for aging; its purpose is “to build a practical, culturally relevant, scientifically credible and scalable model, validated through real-world evidence and translated into better prevention, healthier everyday living and ultimately better health outcomes.”
Asia-Pacific, in that sense, offers an unusually large arena in which to attempt that work – diverse, rapidly aging and far too heterogeneous for easy answers.
If SCI develops as intended, its value may lie less in producing another definition of healthy longevity than in discovering which ideas remain useful when exposed to billions of complicated, ordinary lives. That is where prevention has to work eventually.
The 2026 Asia-Pacific Healthy Longevity International Summit is 1–4 October 2026 at The Hopewell Hotel in Hong Kong – to find out more CLICK HERE.
